anti-CD20 antibody

Phase 3Biologic

anti-CD20 antibody is one of 17 biologic programs targeting Thrombotic Thrombocytopenic Purpura. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thrombotic Thrombocytopenic PurpuraActive, not recruiting

Thrombotic Thrombocytopenic PurpuraPhase 3

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Thrombotic Thrombocytopenic Purpura

#DrugCompanyPhaseTrials

Medrol

Bayer Aspirin

Neoral

1 4

Rayos

RRoxane Laboratories

Phase 3

1 5

Rituxan

Roche

Phase 2

5 6

Plasma Exchange

Sanofi

Phase 3

1 7

Danocrine

Sanofi

Phase 2

1 8

Vyvgart

Argenx

Phase 2

1 9

Immunosuppressive Treatment

Sanofi

Phase 3

1 10

CABLIVI

GGenzyme, a Sanofi Company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Recruiting

B-Cell

NCT06586177

Clinical

Trials by Indication[1]

Thrombotic Thrombocytopenic Purpura1 trial

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

Completed· Sanofi logo

Sanofi·Phase 3·NCT05468320·51 enrolled

B-Cell1 trial

Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies

Recruiting·HHeinrich-Heine University, Duesseldorf··NCT06586177·100 enrolled

HBV1 trial

Optimizing HBV Management During Anti-CD20 Antibodies

Completed·TThe University of Hong Kong··NCT03155984·83 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for anti-CD20 antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-CD20 antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-CD20 antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Sanofi

anti-CD20 antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Thrombotic Thrombocytopenic Purpura1 trial

B-Cell1 trial

HBV1 trial

References

Drug Info

Quick Facts

Related News